AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Current health news highlights include debates over Medicare pricing for drugs like Ozempic and Wegovy, management shifts ...

AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...

AstraZeneca (AZN) changes key management roles in China as the company emerges from several scandals involving its executives ...

AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...

AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), a pharmaceutical giant with a market capitalization of $207.67 billion and ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® ...

(Alliance News) - AstraZeneca PLC on Friday said its drug Calquence, in combination with chemoimmunotherapy, has received approval from the US Food & Drug Administration for the treatment of adult ...

From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on IONS stock, giving a Buy rating on January 13.Stay Ahead of the ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...